Advanced in X-Linked Lymphoproliferative Disease

Dr. Donald B. Kohn

Pediatric Hematology Oncology
4650 W Sunset Blvd, Ms# 62, 
Los Angeles, CA 
Clinical Trials:Currently Recruiting for 1 Trial
41 Years of Experience
Advanced in X-Linked Lymphoproliferative Disease
4650 W Sunset Blvd, Ms# 62, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Donald Kohn is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Kohn has been practicing medicine for over 41 years and is rated as an Advanced provider by MediFind in the treatment of X-Linked Lymphoproliferative Disease. His top areas of expertise are Severe Combined Immunodeficiency (SCID), Adenosine Deaminase Deficiency, X-Linked Severe Combined Immunodeficiency, Hemoglobinopathy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 192 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of X-Linked Lymphoproliferative Disease.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Optima Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

4650 W Sunset Blvd, Ms# 62, Los Angeles, CA 90027

Additional Areas of Focus

Dr. Kohn has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease
Enrollment Status: Recruiting
Publish Date: September 20, 2024
Intervention Type: Drug
Study Drug: CRISPR_SCD001
Study Phase: Phase 1/Phase 2
A Two-Part, Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
A Two-Part, Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Biological
Study Drug: Lentiviral G1XCGD Gene Therapy
Study Phase: Phase 1/Phase 2
Clinical Research Study of Autologous Stem Cell Transplantation for Sickle Cell Disease (SCD) Using Peripheral Blood CD34+ Cells Modified With the Lenti/G-βAS3-FB Lentiviral Vector
Clinical Research Study of Autologous Stem Cell Transplantation for Sickle Cell Disease (SCD) Using Peripheral Blood CD34+ Cells Modified With the Lenti/G-βAS3-FB Lentiviral Vector
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2024
Intervention Type: Biological
Study Drug: ?AS3-FB vector transduced peripheral blood CD34+ cells
Study Phase: Phase 1/Phase 2
Multi-site Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer
Multi-site Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Biological
Study Drugs: Busulfan, Bone Marrow Cell Infusion
Study Phase: Phase 1/Phase 2
Efficacy and Safety of Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for Human ADA Gene in Subjects With Severe Combined Immunodeficiency Due to ADA Deficiency
Efficacy and Safety of Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for Human ADA Gene in Subjects With Severe Combined Immunodeficiency Due to ADA Deficiency
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Genetic, Drug
Study Phase: Phase 1/Phase 2
A Single Arm, Open Label Clinical Study to Enable Process Validation of Commercial Grade Ex Vivo Hematopoietic Stem Cell Gene Therapy (OTL-101) in Subjects With Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)
A Single Arm, Open Label Clinical Study to Enable Process Validation of Commercial Grade Ex Vivo Hematopoietic Stem Cell Gene Therapy (OTL-101) in Subjects With Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)
Enrollment Status: Withdrawn
Publish Date: August 03, 2022
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
View 5 Less Clinical Trials

192 Total Publications

Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.
Journal: The New England journal of medicine
Published: October 15, 2025
Similar Doctors
Advanced in X-Linked Lymphoproliferative Disease
Dr. Gay M. Crooks
Pediatric Hematology Oncology
Advanced in X-Linked Lymphoproliferative Disease
Dr. Gay M. Crooks
Pediatric Hematology Oncology
10833 Le Conte Ave, Site 265, 
Los Angeles, CA 
 (9.0 miles away)
310-825-0867
Languages Spoken:
English

Gay Crooks is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Crooks is rated as a Distinguished provider by MediFind in the treatment of X-Linked Lymphoproliferative Disease. Her top areas of expertise are Severe Combined Immunodeficiency (SCID), Adenosine Deaminase Deficiency, X-Linked Lymphoproliferative Disease, Purine Nucleoside Phosphorylase Deficiency, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kohn's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile